neoag
Neoantigen × AI
Daily research signal
№60Brief2026-10-28

Moderna, Merck vaccine cuts melanoma recurrence risk 42%

Personalized neoantigen medicine advanced on two fronts today: Moderna and Merck reported a 42% reduction in two-year melanoma recurrence risk for their custom mRNA vaccine intismeran in the most advanced study of the modality to date, while Neogap Therapeutics' first-in-human pTTL trial in stage IV colorectal cancer is no longer recruiting.Yahootrial

The pairing shows the field's differentiation shifting from target identification to execution—algorithmic neoantigen selection and single-patient manufacturing on the cell-therapy side, mRNA industrialization on the vaccine side.Yahootrial For investors, adjuvant melanoma now has a validated personalized-vaccine template, and a safety readout for neoantigen-stimulated autologous cells is the next catalyst.Yahootrial

2new stories
ClinicaltodayNew

A First-In-Human Trial of pTTL in Advanced Colorectal Cancer

Neogap Therapeutics' Phase 1/2 first-in-human study of pTTL is now active-not-recruiting, so enrollment is closed and safety/tolerability data in stage IV colorectal cancer are the near-term readout. pTTL is a fully autologous ATMP: tumor-draining lymph node T cells are expanded ex vivo with recombinant neoantigen proteins (NAG) built from mutations selected by Neogap's in-house PIOR software after tumor NGS, then administered as a single IV dose. The trial is an early test of whether neoantigen-stimulated autologous T cells—rather than a vaccine—can deliver on personalization in CRC, with every product manufactured for one individual patient.

Colorectal cancer
clinicaltrials · today · Neogap Therapeutics AB

Also new today01

01
Clinical6 days agoNew

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning - Yahoo

Moderna and Merck reported that intismeran, a custom-built mRNA vaccine matched to each patient's tumor, cut the risk of melanoma returning by 42% two years after surgery when added to standard post-surgery treatment—the most advanced readout to date for personalized cancer vaccines. The adjuvant melanoma result is the field's clearest efficacy signal yet and strengthens the case for the partners' oncology programs, with mRNA vaccine approaches also in testing in lung, kidney and pancreatic cancers. Independent observers, including study investigator Hussein Tawbi of MD Anderson and Parker Institute CEO Karen Knudsen, framed the data as a major validation for the field.

mRNA vaccinesMelanomaPancreatic cancerModernaMerck
news · 6 days ago · Yahoo

Explore the field

TopicsTrialsLearn